Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents
Launched by CENTRE FOR ADDICTION AND MENTAL HEALTH · Apr 15, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to better treat children with disruptive behavior, which can include conditions like Attention Deficit Hyperactivity Disorder (ADHD) and Conduct Disorder. The researchers want to see if creating personalized profiles for both the child and their parents—based on their psychological and emotional needs—can help predict how well they will respond to two types of treatments: cognitive behavioral therapy for the child and Behavioral Parent Training for the parents.
To participate, children aged 2 to 18 who show signs of disruptive behavior and have significant difficulties in relationships or school may be eligible. Parents must be willing to join a group treatment program. However, children with autism or significant cognitive delays, as well as those who prefer individual treatment, will not be included. Participants can expect to take part in group sessions designed to support both the child and the parents, helping them learn effective strategies to manage behavior. This trial is currently recruiting, so it’s a great opportunity for families looking for support.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Child is borderline/clinically at risk on the Child Behaviour Checklist (CBCL) or Teacher Report Form (TRF) (T-score greater than or equal to 60 on Externalizing Problems composite scale or a T-score greater than or equal to 65 on the Oppositional Defiant Disorder and/or Conduct Disorder scales)
- • Child has clinically severe impairment in the interpersonal relations (greater than 3), functioning in schoolwork (greater than 3), or total domains (greater than 15) on the Columbia Impairment scale.
- • Parent is able and willing to participate in a group treatment
- Exclusion Criteria:
- • Child has an ongoing query or diagnosis of Pervasive Developmental Disorder or Autism or Asperger's Disorder
- • Evidence of cognitive delays or an intellectual disability (based on the Kauffman Brief Intelligence Test-2 (KBIT-2), verbal and/or IQ composite standard score below 80 or collateral information)
- • Child behaviour or emotional functioning that make group participation not possible
- • Child preference for individual treatment.
- • Parent behaviour or emotional functioning that make group participation not possible
- • Parent preference for individual treatment.
About Centre For Addiction And Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada’s leading mental health and addiction teaching hospital, dedicated to advancing research, clinical care, and education in the field of mental health. With a commitment to improving the lives of individuals affected by mental illness and addiction, CAMH conducts innovative clinical trials aimed at developing and evaluating new treatment approaches. The institution fosters a collaborative environment that brings together researchers, clinicians, and community partners to translate scientific findings into effective interventions, ensuring the highest standards of care and support for patients. Through its robust research initiatives, CAMH strives to enhance understanding of mental health disorders and promote evidence-based practices in the treatment of addiction and mental health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Brendan F. Andrade, PhD
Principal Investigator
Centre for Addiction and Mental Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported